

Miquel Baquero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5679392/publications.pdf>

Version: 2024-02-01

17
papers

1,400
citations

759233

12
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1502
citing authors

#	ARTICLE	IF	CITATIONS
1	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
2	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
3	Free radicals in Alzheimer's disease: Lipid peroxidation biomarkers. <i>Clinica Chimica Acta</i> , 2019, 491, 85-90.	1.1	96
4	Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 295-302.	0.6	81
5	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 85.	6.2	69
6	Lipid peroxidation in neurodegeneration. <i>Clinica Chimica Acta</i> , 2019, 497, 178-188.	1.1	62
7	Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer Disease detection. <i>Free Radical Biology and Medicine</i> , 2018, 124, 388-394.	2.9	51
8	Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. <i>Journal of Proteomics</i> , 2019, 200, 144-152.	2.4	50
9	Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers. <i>Talanta</i> , 2018, 184, 193-201.	5.5	44
10	New screening approach for Alzheimer's disease risk assessment from urine lipid peroxidation compounds. <i>Scientific Reports</i> , 2019, 9, 14244.	3.3	25
11	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 79, 131-141.	3.1	23
12	Validated analytical method to determine new salivary lipid peroxidation compounds as potential neurodegenerative biomarkers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 742-749.	2.8	21
13	Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis. <i>Antioxidants</i> , 2021, 10, 1043.	5.1	13
14	Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer's Disease Differential Diagnosis. <i>Antioxidants</i> , 2020, 9, 649.	5.1	11
15	Plasma isoprostanooids assessment as Alzheimer's disease progression biomarkers. <i>Journal of Neurochemistry</i> , 2021, 157, 2187-2194.	3.9	8
16	Isoprostanooids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer's Disease. <i>Antioxidants</i> , 2020, 9, 407.	5.1	4
17	Assessment of Screening Approach in Early and Differential Alzheimer's Disease Diagnosis. <i>Antioxidants</i> , 2021, 10, 1662.	5.1	2